Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRWD NASDAQ:LXRX NASDAQ:RIGL NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$4.09-1.8%$3.70$0.53▼$5.78$662.83M0.293.88 million shs582,674 shsLXRXLexicon Pharmaceuticals$1.84+9.2%$1.66$0.51▼$1.95$781.69M0.972.61 million shs2.06 million shsRIGLRigel Pharmaceuticals$26.64+1.5%$29.07$17.65▼$52.24$493.67M1.21369,643 shs79,006 shsSABSSAB Biotherapeutics$3.96-3.2%$3.88$1.60▼$6.60$199.37M0.55569,718 shs1.24 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals-13.66%+0.97%+20.52%-8.55%+426.52%LXRXLexicon Pharmaceuticals+5.00%+4.35%+5.00%+36.59%+148.52%RIGLRigel Pharmaceuticals-1.61%-9.20%-8.67%-23.16%+42.07%SABSSAB Biotherapeutics+7.63%+9.36%+8.78%-1.92%+142.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$4.09-1.8%$3.70$0.53▼$5.78$662.83M0.293.88 million shs582,674 shsLXRXLexicon Pharmaceuticals$1.84+9.2%$1.66$0.51▼$1.95$781.69M0.972.61 million shs2.06 million shsRIGLRigel Pharmaceuticals$26.64+1.5%$29.07$17.65▼$52.24$493.67M1.21369,643 shs79,006 shsSABSSAB Biotherapeutics$3.96-3.2%$3.88$1.60▼$6.60$199.37M0.55569,718 shs1.24 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals-13.66%+0.97%+20.52%-8.55%+426.52%LXRXLexicon Pharmaceuticals+5.00%+4.35%+5.00%+36.59%+148.52%RIGLRigel Pharmaceuticals-1.61%-9.20%-8.67%-23.16%+42.07%SABSSAB Biotherapeutics+7.63%+9.36%+8.78%-1.92%+142.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRWDIronwood Pharmaceuticals 2.43Hold$6.2352.26% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.15126.16% UpsideRIGLRigel Pharmaceuticals 2.50Moderate Buy$51.5093.33% UpsideSABSSAB Biotherapeutics 2.63Moderate Buy$10.50165.08% UpsideCurrent Analyst Ratings BreakdownLatest SABS, IRWD, LXRX, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$71.00 ➝ $69.004/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/21/2026RIGLRigel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/10/2026SABSSAB Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/2/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.003/23/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/12/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.003/12/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/11/2026SABSSAB Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $14.003/10/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.10 ➝ $2.303/10/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRWDIronwood Pharmaceuticals$296.15M2.25$0.22 per share18.76($1.61) per share-2.54LXRXLexicon Pharmaceuticals$49.80M15.61N/AN/A$0.30 per share6.12RIGLRigel Pharmaceuticals$294.28M1.67$6.73 per share3.96$21.61 per share1.23SABSSAB Biotherapeutics$1.32M152.89$0.36 per share11.12$3.18 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRWDIronwood Pharmaceuticals$24.02M$0.1331.27N/AN/A8.11%-13.72%10.95%N/ALXRXLexicon Pharmaceuticals-$50.34M-$0.14N/AN/AN/A-101.08%-41.94%-22.03%N/ARIGLRigel Pharmaceuticals$367.02M$18.911.437.14N/A121.50%47.99%32.40%N/ASABSSAB Biotherapeutics$13.27M-$2.32N/AN/AN/AN/A15.17%12.51%5/12/2026 (Estimated)Latest SABS, IRWD, LXRX, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.2125N/AN/AN/A$0.13 millionN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 million3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/A3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million3/3/2026Q4 2025RIGLRigel Pharmaceuticals$1.33$1.14-$0.19$13.54$68.70 million$69.80 million2/25/2026Q4 2025IRWDIronwood Pharmaceuticals$0.02-$0.01-$0.03-$0.01$86.10 million$47.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRWDIronwood PharmaceuticalsN/A1.131.13LXRXLexicon Pharmaceuticals0.464.884.87RIGLRigel Pharmaceuticals0.042.622.30SABSSAB Biotherapeutics0.029.469.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRWDIronwood PharmaceuticalsN/ALXRXLexicon Pharmaceuticals74.70%RIGLRigel Pharmaceuticals66.23%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipIRWDIronwood Pharmaceuticals12.70%LXRXLexicon Pharmaceuticals14.00%RIGLRigel Pharmaceuticals10.47%SABSSAB Biotherapeutics25.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRWDIronwood Pharmaceuticals220163.06 million142.35 millionOptionableLXRXLexicon Pharmaceuticals140423.68 million364.37 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.55 millionOptionableSABSSAB Biotherapeutics14050.95 million38.18 millionNot OptionableSABS, IRWD, LXRX, and RIGL HeadlinesRecent News About These CompaniesSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMay 5 at 8:30 AM | globenewswire.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | americanbankingnews.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by BrokeragesMay 3, 2026 | marketbeat.comSAB Biotherapeutics (SABS) Expected to Announce Earnings on FridayMay 1, 2026 | marketbeat.comShort Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%April 30, 2026 | marketbeat.comSAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4% - Here's What HappenedApril 30, 2026 | marketbeat.comEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB ...April 29, 2026 | caledonianrecord.comCSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026April 22, 2026 | globenewswire.comSAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 DiabetesApril 15, 2026 | seekingalpha.comSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressApril 15, 2026 | markets.businessinsider.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from AnalystsApril 8, 2026 | marketbeat.comSAB Biotherapeutics closes $85 million public offeringMarch 20, 2026 | thepharmaletter.comTSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2026 | globenewswire.comSAB Biotherapeutics Launches Major Equity Financing OfferingMarch 19, 2026 | tipranks.comSAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 MillionMarch 17, 2026 | quiverquant.comQSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 17, 2026 | globenewswire.comSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMarch 17, 2026 | globenewswire.comSAB Biotherapeutics Highlights New Phase 1 SAB-142 DataMarch 10, 2026 | tipranks.comSAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 DiabetesMarch 10, 2026 | globenewswire.comSAB BIO Reports Full Year 2025 Financial Results and Business HighlightsMarch 9, 2026 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesMarch 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSABS, IRWD, LXRX, and RIGL Company DescriptionsIronwood Pharmaceuticals NASDAQ:IRWD$4.09 -0.08 (-1.82%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$1.84 +0.16 (+9.23%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Rigel Pharmaceuticals NASDAQ:RIGL$26.64 +0.40 (+1.52%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.SAB Biotherapeutics NASDAQ:SABS$3.96 -0.13 (-3.15%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
